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INTRODUCTION 
AIDS – the acquired immuno deficiency syndrome 
called slim disease is a fatal illness caused by a retrovirus known as 
human immuno deficiency virus which breakdown the body’s immune 
system  leaving  the  victim  Vulnerable  to  a  host  of  life  threatening 
opportunistic infections, neurological disorders or unusual malignancy. 
Strictly speaking the term AIDS refers only to the last stage of the HIV 
infection.5
                     The human immunodeficiency virus (HIV) infection 
has  spread  worldwide,  with  various  adverse  health  and  economic 
implications,  particularly  in  the  developing  world.  Unless  a  cure  is 
found or life prolonging therapy can be made more widely available, 
the majority of people will remain suffering the profound impacts the 
disease has on their quality of life.56
                     Globally, 33 million people were estimated to be 
living with HIV/AIDS in 2007. The number of HIV-positive TB cases 
and deaths were estimated at 1.39 million cases (15% of all incident 
cases) and  0.48 million deaths, which was 24% of the estimated two 
million HIV deaths in 2007.10,21
In  India,  the  2006  estimates  suggested  that 
national  adult  HIV  prevalence  in  India  was  approximately  0.36  per 
cent,  amounting to 2.34 million (ranging between 2 and 3.1 million) 
people living with HIV and AIDS.Even going by the  conventional figure 
of  40%  of  the  Indian  population  infected  with  Mycobacterium 
tuberculosis, it is estimated that not less than one million persons with 
HIV are co-infected with TB. 
           Considering the fact that the lifetime risk of developing 
TB disease is between 50-60%, India is likely to have not less than one 
lakh patients, needing treatment for both HIV and TB simultaneously at 
any  given  point  of  time.  Free  Anti-Retroviral  Therapy  (ART)  was 
introduced in India in April, 2004, as a component of care, support and 
treatment, in National AIDS Control Program(NACP). 
 The concept of managing HIV disease in India till  that 
time was to treat the opportunistic infections, as and when these were 
identified. Initiation of ART reduces risk of further HIV-related morbidity 
and  mortality.  ART reduces  the  incidence  of  TB  even  in  high  TB 
prevalence countries.21
MILESTONES IN THE HISTORY OF 
HIV 14,4
1. 1981- First report of AIDS case
2. 1983 – HIV identified 
3. 1985 – AZT entered phase I, II trials
4. 1986 – HIV 2 identified, AZT showed survival benefit in AIDS 
Patients
5. 1987 - AZT for Therapy 
6. 1995 – Double nucleoside combination
7. 1996 – Protease Inhibitor, NNRTI introduced
8. 1997 – Concept of full HIV suppression 
9. 1998  –  Dramatic  reduction  in  AIDS  related  morbidity  and 
mortality
10.2001 – Inexpensive  ART available in resource  poor country 
11. 2004 – During April Government of India initiated supply of free 
ART to HIV Patients.
AIM OF THE STUDY
1. To  study  the  clinical  response  to  highly  active 
antiretroviral therapy (HAART)
2. To  study  the  Immunological  response  to  highly  active 
antiretroviral therapy (HAART)
3. To  study  the  functional  status  improvement  to  highly 
active antiretroviral therapy (HAART)
4. To study the prevalence of HIV and TB co-infection 
Review of literature
Introduction
               No other disease in history has been studied so 
extensively in a short period as AIDS. The first documented evidence 
of the disease appeared in United States in 1981, followed by reports 
from other parts of the world.  HIV entered India a few years later. The 
first  case of  AIDS was reported in  1986. 5 Antiretroviral  therapy for 
treatment of Human Immuno deficiency Virus type 1 (HIV-1) infection 
has improved steadily since the advent of combination therapy in 1996. 
More recently, new drugs have been approved, offering added dosing 
convenience  and  improved  safety  profiles,  while  some  previously 
popular drugs are being used less often as their drawbacks become 
better defined.36
AGENT FACTOR
When  the  Virus  was  first  identified  it  was  called 
Lymphadenopathy associated Virus, then renamed as Human T cell 
lymphotropic virus III. In May 1986, the international committee on the 
taxonomy gave it a new name: Human immune deficiency virus (HIV) 5
STRUCTURE42
Belongs to the lentivirus subgroup of the family retroviridae. HIV 
is a spherical  envelop virus about 90-120nm in size. Nucleocapsid has 
an outer icosahedral shell and an inner cone shaped  core, enclosing 
the  ribonucleo  proteins.  The  genome  is  diploid,  Composed  of  two 
identical  Single stranded, positive sense. RNA copies . In association 
with  Viral  RNA,   the  reverse  transcriptase  enzyme,  Which  is  a 
characteristic feature of retroviruses.
VIRAL GENES AND ANTIGENS 42
The genome of HIV contains the three structural genes, gag, pol 
and env characteristics of all retroviruses as well as other nonstructural 
and regulatory genes specific for the virus.
MAJOR ANTIGEN OF HIV
A. Envelope Antigens:
Spike Antigen – gp 120 (Principle envelope Antigen)
Transmembrane pedicle protein – gp 41
B. Shell Antigen:
Nucleocapsid protein - P – 18
C. Core Antigens:
Principle Core Antigen –P24
Other Core Antigen - P15, P55
D. Polymerase Antigens :
 P31, P51, P66
STAGES OF VIRAL REPLICATION 12,8
STAGES STEPS IN REPLICATION DRUG TARGETS
1 Attachment  to CD4 receptor ------------------------
2 Binding  to  co-receptor  CCR5  or 
CXCR4
CCR5/CXCR4 receptor inhibitors
3 Fusion Fusion inhibitors
4 Reverse Transcription Nucleoside  and  non-nucleoside 
Reverse transcriptase inhibitors
5 Integration Integrase inhibitors
6 Transcription -------------------------
7 Translation -------------------------
8 Cleavage  of  polypeptides  and 
assembly
Protease inhibitors
9 Viral release -------------------------
EPIDEMIOLOGY: 3,38,44
India  has the World’s  largest  population suffering from 
AIDS after  South Africa and Nigeria.  HIV infection in India declined 
drastically in recent  years from 5.5m in 2005 to below 2.5million in 
2007.
             Nationwide HIV Prevalence rate among adults stood at 
0.34%  in  2007.Main  factor  which  contributed  to  India‘s  large  HIV 
infected population are extensive labor migrate, low literacy level.
1. World
Global summary of the AIDS. Epidemic as on Dec 2007
Numbers of people living with HIV -  2007.
Total  : 33.2million
Adults : 30.8million
Women   : 15.4million
Children :  2.5million
People newly infected with HIV in 2007
Total : 2.5million
Adults : 2.1million
< 15 years : 4, 20,000
AIDS Death in 2007
Total : 2.1 million
Adults : 1.7million
< 15 yrs :  3, 30,000
2. In India
2.4 million people living with HIV / AIDS 
Adults HIV prevalence 0.34% (0.25% - 0.43%)
Among PLHA 39% were females 3.5% were children
Based  on  Sentinel  Surveillance  data,  HIV  prevalence  in  adults 
population classified into 3 groups of states in the country.(5)
Group I: High  prevalence  state:  Includes   Maharashtra,  TamilNadu, 
Karnataka, Andhra Pradesh, Manipur and Nagaland where the 
HIV infection has crossed 5% in high risk groups and ≥ 1% in 
antenatal women.
Group II: Moderate  Prevalence  State:  Includes   Gujarat,  Goa, 
Pondicherry  where  HIV  infection  has  crossed  5%  or  more 
among  high  risk  groups  but  the  infection  is  below  1%  in 
antenatal women.
Group III: Low prevalence  States:  Includes  remaining  states  where  the 
HIV infection in any of the high risk groups is still less than 5% 
and < 1% in Antenatal women.
Annual Sentinel Surveillance 5,30
In  India,  the  districts  have  been  classified  according  to  the 
epidemiological  and  Vulnerability  criteria  using  the  Sentinel 
Surveillance data for the last 3 years.
Categories of Districts
A -    > 1% ANC prevalence in district in anytime of the sites in 
the last 3 years
B-     < 1% ANC, >5% prevalence in High risk groups (HRG).
C-     < 1% ANC, <5% HRG with known hot spots
D-      < 1% ANC, <5% in HRG with no known hot spots.
HRG (High  Risk  Groups)  –  STD  Population,  Female  sex 
workers 
              MSM -men having sex with men 
                        IDU - Intra Venous drug users
ANC    :    Antenatal clinic
Hot spots:   Migrants, Truckers, Large aggregation of factory 
workers, Tourists.
 A recent  study published in  the British medical  journal  "The 
Lancet"  in  (2006)  reported  an  approximately  30%  decline  in  HIV 
infections among young women aged 15 to 24 years attending prenatal 
clinics in selected southern states of India from 2000 to 2004 where 
the  epidemic is  thought  to  be concentrated.  The authors  cautiously 
attribute observed declines to increased condom use by men who visit 
commercial  sex  workers  and  cite  several  pieces  of  corroborating 
evidence.
MODES OF TRANSMISSION :44
The modes of transmission of HIV are sexual (man to man, 
Heterosexual and oral), parenteral (blood or blood product recipients, 
injection drug users and those experiencing occupational injury) and 
vertical route. 
CLINICAL  FEATURES 34,35,38
  Asymptomatic HIV (clinical latency)
 Patient often unaware of infection
 Immune system able to control virus to limited extent
 Able to transmit HIV to others
 Symptomatic HIV
 Minor to moderately severe symptoms
 Recurrent symptoms
 AIDS
 Severe  immunosuppression  associated  with  opportunistic 
infections or malignancies
 Without antiretroviral treatment
 30% will develop AIDS in 3 years
 90% will develop AIDS within 10 years
                             
Neurologic symptoms-12%Nausea&vomiting-27%Rash-70%
Thrush-12%Headache-32%Pharyngitis-70%
Weight loss-13%Diarrhea-32%Adenopathy-74%
Hepatosplenomegaly-14%Myalgias-54%Fever-96%
Acute Retroviral Syndrome
BASELINE EVALUATION 51
A  standard  clinical  and  laboratory  evaluation  is 
recommended
prior to initiation of ART. It is intended to establish the baseline status 
for  future  comparison,  individualizing  ART  according  to  patient’s 
clinical status and preferences, and ruling out active OIs.
History
Points to be elicited in history taking:
1. HIV specific symptoms- present and past
2. Genital ulcers and other sexually transmitted diseases
3. Personal history- smoking, alcohol, drugs
4. Past history of any coronary artery disease
5. High risk behavior- partner’s HIV sero-status if known
6. Women- gynaecological history, past pregnancies, contraception
7.  Family  history  of  coronary  disease,  hypertension,  diabetes  and 
hyperlipidemia
8.  Treatment  history:  any past  or  current  use  of  ARVs (useful   for 
designing ART regimen),  sexual partners ARV use, ARV use during 
pregnancy.
Physical examination
A routine physical examination is essential prior to initiating
ART. Following evaluation is recommended:
1. Body weight, height, Body Mass Index
2. Temperature/Lymph-node
3. Dermatological/Oral cavity: oral candidiasis, oral hairy leukoplakia
4. Systemic examination
Laboratory evaluation
The purpose of baseline laboratory evaluation is to stage HIV 
disease, rule out concomitant infections and determine baseline safety 
parameters. The following tests are recommended:
1. Confirm HIV infection : A pre-requisite prior to ART  initiation, it also 
is  needed  to  rule  out   HIV-2  infection.  Nonnucleoside  reverse 
transcriptase inhibitor’s (NNRTIs) have no activity against HIV-2.
2. Specific investigations to rule out OIs
3.  CD4  counts  :  Estimated  by  flow-cytometry.  Alternative  low  cost 
technologies  are  becoming  available,  however  further  evidence  is 
needed to recommend its routine use in clinical practice.
4. CBC : Baseline Hemoglobin and WBC counts are needed to monitor 
hematological toxicity on Zidovudine (ZDV).
5.  LFTs :  Necessary to  find evidence of  hepatitis,  particularly when 
NVP use is contemplated.
6.  Urine  routine:  To  evaluate  proteinuria  and  sugar  (necessitate 
estimation of blood glucose)
7.  Creatinine  :  Dose  of  some  nucleoside  reverse  transcriptase 
inhibitors (NRTIs) has to be adjusted according to creatinine clearance.
8.  HBsAg  :  To  rule  out  concomitant  hepatitis  B  infection,  this  can 
influence choice of ARV      regimen. Additionally, abrupt stopping of 
anti-HBV drugs like lamivudine and tenofovir is not recommended in 
patients  with  chronic  hepatitis  B  coinfection  since  it  may  result  in 
hepatitis B flare.
9. Chest X-ray : To rule out TB or other pulmonary infection.
Antiretroviral Drugs approved for use 1,7
NRTI     NNRTI      PI    Entry 
inhibitor
    Zidovudine(ZDV)      Nevirapine(NVP)     Saquinavir(SQV) 
       Enfuvirtide(T-20)
    Stavudine(d4T)      Efavirenz(EFV)     Indinavir (IDV)        Nucleotide 
RTI     Lamivudine (3TC)     Delavirdine     Ritonavir(RTV) 
tenofovir(TDF)
   Didanosine(ddI)      (DLV)         Nelfinavir(NFV       CCR 5 
Antagonist
   Zalcitabine(ddC)     Lopinavir(LPV/r)       Maraviroc
   Abacavir(ABC)     Amprenavir(APV)
   Emtricitabine(FTC)     Fos-amprenavir(FPV)
    Integrase Inhibitors    Tiprinavir(TPV)
    Raltegravir                                              Atazanavir(ATV)
           Dosage of antiretroviral drugs used in the first-line ART regimens 7,27
Drug Dosage
1. Zidovudine (AZT) 300 mg twice daily
2. Lamivudine (3 TC) 150 mg twice daily
3. Nevirapine (NVP)            200 mg twice daily, except for   the first 2 
weeks
4. Efavirenz (EFV)  600 mg once daily
5. Stavudine (d4T)  30 mg twice daily
Medical eligibility to start ART: 6,47
1. If CD4 testing available: 
1. CD4 < 200 at any WHO clinical stage
2. WHO clinical stage 4 : No matter of CD4 count
3. WHO clinical stage 3 : Consider ART if CD4, < 350 and initiate if 
CD4 < 200cells/mcl.
4. WHO clinical stage 1 & 2: CD4 < 200cells/mcl
2. IF CD4 testing not available: 
WHO clinical stage 3 & 4.
3. Post exposure prophylaxis: 2
1. A Combination of 2 nucleoside reverse transcriptase inhibitor for 
4 weeks duration for less severe exposure.
2. A combination  of  2  nucleoside  reverse  transcriptase  inhibitor 
plus a 3rd drug (protease inhibitor) for 4 weeks duration for more 
severe exposure.
3. Selecting the Regimen: 6,16,18
 As a general rule should not initiate ART during a severe acute 
opportunistic infection or other severe illness.
1. If the patient on ATT  - Efavirenz based regimen
2. Is there Anaemia - <8gm% - Stavudine based regimen
3. If  there is Jaundice or known liver disease?
Non nevirapine based regimen
4. If  the  patient  is  diabetic  (or)  heart  diseases? 
Individualized according to patient’s condition
Goal of ART 2,6,15,48
1. Clinical Goals: Prolongation of life and Improvement in  quality of 
life
2. Virological Goals: Greatest possible reduction in viral load for as 
long as possible
3. Immunological  Goals:  Immune  reconstitution  that  is  both 
quantitative and qualitative
4. Therapeutic Goals: Rational sequencing of drugs in a fashion that 
achieves  clinical,  Virological  and  Immunological  goals  while 
maintaining  future  treatment   options,  limiting  drug  toxicity  and 
facilitating adherence.
5. Reduction of HIV transmission in individuals: Reduction of HIV 
transmission by suppressing  the viral load.
Adherence to ART:
 95 % Adherence : less than 3 doses missed /month
 80 – 95% Adherence: 3-12 doses missed/month
 <80% Adherence: ≥ 12 doses missed /month
LABORATORY MONITORING OF PATIENT’S WITH HIV INFECTION 
DURING TREATMENT
1.CD4 + T cell count
2. HIV RNA determinations
      3. HIV resistance testing
4. TB / HIV co- infection assessment
 
Treatment  failure: 9,19
1. Increased viral load-Virological failure
2. decreased CD4 count -Immunological failure
3. Increased opportunistic infection- Clinical failure
Pulmonary TB
This is  most common form of TB disease. The presentation 
depends on the degree of immunosuppression:
In patients with  mild immunosuppression, chest X-ray (CXR) 
typically  shows  upper  lobe  and/or  bilateral  infiltrates,  cavitation, 
pulmonary fibrosis and shrinkage. The clinical picture often resembles 
post-primary pulmonary TB (PTB),  and the sputum smear is usually 
positive.
 In severely immune suppressed patients, the features of the 
disease  are  atypical,  resembling  those  of  primary  TB.  The  sputum 
smear  can  often  be  negative  and  CXR shows  interstitial  infiltrates, 
especially  in  the  lower  zones,  with  no  features  of  cavitation  and 
fibrosis.  Unilateral  or  bilateral  infiltrates  are  seen more  often  in  the 
lower lobes than in the upper lobes and typical cavities are seen in 
only 25% of patients.
In  persons  with  advanced  HIV  infection,  disseminated  and 
extrapulmonary TB are more common. The most common forms are 
lymphadenitis,  pleural  effusion,  pericarditis,  miliary  disease  and 
meningitis. The most important symptoms are: cough lasting longer 
than 3 weeks and not responding to the usual  antibiotic treatment, 
purulent/blood-stained sputum, evening fever, night sweats and weight 
loss.
Diagnostic tests:
Sputum examination:
 Microscopic  examination  of  sputum  stained  by  the  Ziehl–
Neelsen (ZN) methodis the diagnostic test of choice. A PTB suspect 
should submit three sputum samples for microscopy.At first visit, the 
patient should provide an on-the-spot sputum sample. Give the patient 
a sputum container to take home for an early morning sample on the 
following day (that is, on day 2).  An inpatient can provide two early 
morning sputum samples.
Radiological examination: 
The classical pattern seen on CXR in TB is upper lobe infiltrates 
with cavitation. However, in severe immunosuppression, the affected 
region is mostly extrapulmonary in the form of hilar adenopathy and 
pleural  effusion.  There  may  be  upper  zone  infiltrates  or  a  military 
pattern,  and  atypical  lower  zone  infiltration  of  the  lung  fields  as 
described above. Cavitation may not be seen in patients with severe 
immune suppression. It is not possible to make a confirmed diagnosis 
of TB based on the X-ray picture alone.
Purified protein derivative (PPD) test: 
PPD is likely to be positive at higher CD4 counts. As the count 
falls to less than 100 cells/mm3 it  may become negative. It  has no 
diagnostic significance.
Fine-needle aspiration cytology (FNAC):
 An FNAC from a lymph node may show AFB in patients with 
HIV infection.
Other tests: 
An ultrasonography of the abdomen may show enlarged intra-
abdominal  lymph  nodes  and  multiple  hypoechoic  lesions  in  organs 
such as the spleen or liver.
 Lumbar puncture (LP):
Done in suspected cases of TB meningitis may have a turbid or 
viscous  appearance,  with  100–300  lymphocytes/  mm3,  0–200 
polymorphs/mm3, 0.5–3 g/litre of protein, and half the blood value of 
glucose. 
CT scan
 can pick up brain tuberculomas, hydrocephalus or enhancement 
of the basal meninges.
 Bone marrow biopsy and culture
 may demonstrate the presence of the organisms.
Treatment
Standard Directly observed treatment, Short-course (DOTS) 
regimens are to be followed
 according  to  the  RNTCP  programme  in  India.  The  patient 
should  be  referred  to  a  DOTS  centre  for  antituberculosis  therapy 
(ATT).  The  regimens  used  for  the  treatment  of  pulmonary  and 
extrapulmonary  tuberculosis  are  same  in  both  HIV-positive  and 
-negative individuals. Around 6–8 months of treatment appears to be 
sufficient for extrapulmonary disease at many sites. Twelve months of 
therapy is  recommended  for  miliary  TB,  bone  or  joint  disease  and 
tubercular  meningitis.  Persistently  positive  sputum culture  after  2–3 
months of therapy suggests the possibility of drug-resistant TB or non-
compliance with therapy.
Revised National Tuberculosis Control Programme (RNTCP)
Treatment  regimens  followed  vary  according  to  the  type  of 
patient (whether the patient is a new case of TB or one who has been 
treated  for  TB  previously),  severity  of  illness  and  response  to 
treatment.
Category I – Regimen used: 2(EHRZ)3 , 4 (HR)3
This  regimen  is  recommended  in  patients  with  new  sputum 
smear-positive  TB,  seriously  ill  smear-negative  TB,  seriously  ill 
extrapulmonary TB, and all new TB patients who voluntarily disclose 
their HIV status.
Category II – Regimen used : 2 (SEHRZ)3/1(EHRZ)/5 (EHR)3
This  regimen  is  recommended  in  patients  with  previously 
treated  smear-positive  TB  (including  relapse,  failure  and  treatment 
after default).
Category III – Regimen used: 2(HRZ)3/4(HR)3
This  regimen  is  recommended  in  patients  with  new  smear-
negative TB, extrapulmonary TB and those who are not seriously ill.
In all categories, 
treatment is given in two phases.
The first or intensive phase consists of treatment lasting for 2–
3  months.  In  the  intensive  phase,  three  to  five  anti-TB  drugs  are 
administered depending on the category of treatment prescribed and 
all the thrice-weekly doses are given under direct observation.
This is followed by the continuation phase, which lasts for 4–5 
months.  In  the  continuation  phase,  the  number  of  anti-TB  drugs 
administered  is  reduced  to  two  or  three  drugs  depending  on  the 
regimen prescribed and only the first dose of the week is given under 
direct supervision and the remaining  two doses in the week are self-
administered.
E  (ethambutol),  H  (isoniazid),  R  (rifampicin),  Z  (pyrazinamide)  and  S 
(streptomycin).
The numbers before the bracket indicate the number of months 
for which the drugs are to be administered.
The number “3” given as a subscript after the bracket indicates 
that the drugs are administered thrice weekly.
Category I and Category III regimens are given for 6 months, 
while the Category II regimen is for 8 months.
Precautions
In HIV-infected TB patients, combining rifampicin with protease 
inhibitors and nevirapine has been found to decrease the levels of all 
the drugs, thereby decreasing the effectiveness of ART and increasing 
the  rifampicin  levels,  leading  to  rifampicin-induced hepatotoxicity.  In 
case  ATT  and  ART  are  used  together,  an  efaviranzbased   ART 
regimen  should  be  followed.  If  oral  candidiasis  is  also  present, 
administration of anti-TB drugs
together with fluconazole can also result in hepatotoxicity. Close 
monitoring for serum transaminases and serum bilirubin is necessary 
for early detection of hepatotoxicity.
Dosages
In adults, the dosages of the drugs are as follows:
Isoniazid 600 mg thrice weekly
Rifampicin 450 mg (600 mg if weight >60 kg) thrice weekly
Pyrazinamide 1500 mg thrice weekly
Ethambutol 1200 mg thrice weekly
Streptomycin 0.75 g thrice weekly (0.5 g in patients >50 years of age).
Materials & Methods
The  study  was  conducted  on  118  HIV  infected  adults  who 
attended the ART centre, Annal Gandhi Memorial Hospital from August 
2007  to  August  2009.  All  patients  were  thoroughly  evaluated  by 
detailed  history,  general  examination,  systemic  examination, 
appropriate Investigations as per proforma.
List  of  Pre  and  Post  treatment  investigation included  the 
following.
1. Hemoglobin
2. Total and differential count
3. Erythrocyte Sedimentation Rate
4. Platelet count
5. Blood sugar
6. Blood urea
7. Serum  creatinine
8. Liver function test
9. X-Ray chest PA view(If necessary)
10.Sputum for AFB (If necessary)
11.CD4 count (6 monthly)
12.Other specific test it needed.
Selection Criteria:
The following criteria are used for selection of HIV patients:
1. Patient should be more than or equal to 20 years
2. The diagnosis of HIV confirmed as per WHO criteria
3. Initiation of HAART according to WHO criteria
Exclusion criteria: 
1. Patient less than 20 years
2. The patients who have already received treatment with 
ART outside
3. Patients  who  died  within  6  months  after  initiation   of 
HAART
4. Patients  who missed more than 12 doses per month
5. Patients who lost follow up after initiation of HAART
Diagnostic criteria
For the purpose of diagnosis, three rapid HIV test kits based on 
different  antigens  /  principle  are  to  be  used.  Blood  samples  are 
processed  for  HIV.  The  test  result  may  be  positive,  Negative  (or 
indeterminate as described below.
Test kit 1(Micro Lisa)  – Positive
Test kit 2 (In stochk )  – Positive
Test kit 3 ( Pareekshak )   –       Positive
 Case reported as positive
Subjects and Methods:
This prospective  study was conducted at  the ART centre, 
Annal Gandhi Memorial Hospital, Trichy from August 2007.
118  HIV  positive  patients  were  selected  as  per  selection 
criteria.  18 patients  excluded subsequently since they lost  follow up or 
poor adherence rate or died within 6 months of treatment.
Patients  were  enquired,  regarding  occupation,  educational 
status personal history, family history and their complaints.
History  was  obtained  in  detail  about  the  marital  status  and 
couples and couple reactivity, children status. 
After receiving consent from the patients, general and systemic 
examinations  were  performed  ,then  laboratory  investigations  were 
done in all patients. 
All patients were examined for opportunistic infections. Patient’s 
weight was recorded during each visit. Nutritional advise was given to 
all patients.
Functional status obtained by history.
Clinical  staging  were  determined  by  clinical  examination  of  the 
patients.
All patients were subjected to relevant investigation as required.
`WHO clinical staging of HIV/AIDS  for adults  6,51
Clinical Stage 1
Asymptomatic
Persistent Generalized Lymphadenopathy
Clinical Stage 2
Moderate unexplained weight loss (under 10% of presumed 
or measured body weight)
Recurrent respiratory tract infections
Herpes zoster
Angular cheilitis
Recurrent oral ulcerations
Papular pruritic eruptions
Seborrhoeic dermatitis
Fungal nail infections
Clinical Stage 3
Unexplained severe weight loss (>10% of  measured body 
weight)
Unexplained chronic diarrhea > 1 month
Unexplained persistent fever > 1 month
Persistent oral candidiasis
Oral hairy leucoplakia
Pulmonary tuberculosis
Severe  bacterial  infections  (e.g.  pneumonia,  empyema, 
pyomyositis)
Acute  necrotizing  ulcerative  stomatitis,  gingivitis,  or 
periodontitis
Unexplained  anemia  (<8  g%),  neutropenia  (<500),  and  or 
chronic          thrombocytopenia (<50,000)
Clinical Stage 4
HIV wasting syndrome
Pneumocystis carinii  pneumonia
Recurrent severe bacterial pneumonia
Chronic  herpes  simplex  infection  (orolabial,  genital  or 
anorectal
of more than one months duration or visceral at any site)
Esophageal candidiasis
Extrapulmonary tuberculosis
Cytomegalovirus disease (retinitis or any other organ)
Central nervous system toxoplasmosis
HIV encephalopathy
Extrapulmonary cryptococcosis including meningitis
Disseminated non-tuberculous mycobacterial infection
Progressive multifocal leucoencephalopathy
Chronic cryptosporidiosis
Chronic isosporiasis
Disseminated mycosis (histoplasmosis)
Recurrent septicemia
Lymphoma (cerebral or B cell Non-Hodgkins)
Invasive cervical carcinoma
Atypical disseminated leishmaniasis
Symptomatic  HIV  associated  nephropathy  or 
cardiomyopathy
Functional status Assessment: 27
As  per  NACO  guidelines,  functional  status  of  the  patients 
before, and after starting treatment was assessed and graded as WAB.
W – Working: Able to perform usual work in or out of the house, 
harvest,   normal activities of playing
A – Ambulatory: Able to perform activities of daily living but not 
able to   Work
B – Bedridden: Not able to perform activities of daily living
CD4 Count Analysis:  27
The specimen were collected and analysed by the BD FACS 
Calibur  flow  cytometer  (Beckton,  Dickinson  &  Company,  San  jose, 
USA), from may 2008,PARTEC cyflow counter was used.
Highly active anti  retroviral  therapy was initiated if  the patient 
meets the WHO criteria for starting treatment.
Initiation of HAART based on CD4+ count and WHO clinical stage
.Before  starting  ART,  tuberculosis  infection  was  specifically 
investigated and if found positive was treated with ATT as per RNTCP 
guidelines. 
ART regimens used are,  27
I. Stavudine + Lamivudine + Nevirapine
II.  Stavudine + Lamivudine + Efavirenz
III.  Zidovudine + Lamivudine + Nevirapine
IV. Zidovudine + Lamivudine + Efavirenz
V. Change over from one to other regimen
Treatment follow up:
After 6 months and 1 year of initiating therapy, patients 
were reexamined in detail for change in
1. Functional status 
2. Clinical stage
3. Body weight
4. CD4 count
5. Opportunistic infections
6. Development of Side effects.
If the patient died after initiating HAART, enquiry was made into cause of 
death.
RESULTS AND OBSERVATIONS
This study was conducted among 118 patients attending 
ART
centre  at  Annal  Gandhi  Memorial  Hospital,  Trichy  with  the  aim  of 
analyzing  Immunological,  clinical  response  and  functional  status 
improvement following highly active retro viral therapy.   The analysis 
revealed the following results as found out among the study population 
of 100 patients.18 patients were excluded from the study because of 
their poor adherence rate, discontinued 
treatment with in 6 months starting treatment and lost follow up.
AGE/SEX DISTRIBUTIONS:
Fig - 1
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When Age distribution was analyzed, most of them belonging to 
the  reproductive  age  group  of  20-50  years.  This  shows  that  HIV 
prevalence  is  high  among  20-50  years  of  age  groups.  When  sex 
distribution was analyzed, there was increased prevalence in  males 
compared to females.
ENTRY POINT
Table - 1
         
Among  our  study  subjects  79%  entered  though  VCTC,  9% 
entered through PPTCT, 12% entered through RNTCP.
EMPLOYMENT STATUS
Table - 2
EMPLOYMENT STATUS
SEX YES NO
MALE 52 28
FEMALE 0 20
TOTAL 52 48
Among our study subjects 52% were employed
MARITAL STATUS
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Fig – 2
When marital status was analysed most of them were married (80%)
FAMILY WISE DISTRIBUTION
               Table - 3
FAMILY WISE DISTRIBUTION 
FAMILY PATIENTS
WIDOWER 2
HUSBAND POSITIVE WIFE 
NEGATIVE(DISCORDANT) 23
HUSBAND NEGATIVE WIFE 
POSITIVE(DISCORDANT) 9
HUSBAND AND WIFE POSITIVE 54
NOT KNOWN 12
TOTAL 100
when analyzing family wise distribution 54% were both husband and 
wife positive. 32% were discordant couples. They were remained as 
discordant throughout the study.
OPPURTUNISTIC INFECTIONS & HIV
Fig – 3
When  opportunistic  infections  were  analyzed  37% of patients 
developed  Oral  Candidiasis  ,  32%  of  the  individuals  developed 
tuberculosis  which  includes  both  pulmonary  and  extra  pulmonary 
tuberculosis  ,  10%  of  patients  developed   Recurrent  bacterial 
infections,where as 40% not  had any oppurtunistic infections.
ART REGIMEN
                     Fig –4
In  this  study  population  most  of  the  patients  received  I  &III 
regimen. Change over from one regimen to other regimen was mainly 
due to Nevirapine rash and due to initiation of ATT.
TUBERCULOSIS &HIV CO INFECTION    
    Table - 4
Significantly  higher  numbers  of  HIV  patients  eligible  for 
receiving  ART  are  also  suffering  from  TB  need  an  anti  TB 
treatment. Significant number of patients referred from RNTCP 
for screening found to have HIV.
TUBERCULOSIS & INITIAL CD4 COUNT
Table - 5
TUBERCULOSIS & INITIAL CD4 COUNT
CD4 COUNT PERCENT
<100 15
100 TO 200 12
200 TO 300 4
> 300 1
TOTAL 32
Incidence of tuberculosis more common in HIV patients 
who had CD4 count of less than 200 per mcl.
EXTRAPULMONARY  TUBERCULOSIS & INITIAL CD4 
COUNT
0 1 2 3 4
< 100
100 TO 200
200 TO 300
> 300 
EXTRA PULMONARY TUBERCULOSIS& CD4 
COUNT 
NO OF PATIENTS 
                   Fig - 5
Incidence of extra pulmonary tuberculosis more common in HIV 
patients who had CD4 count of less than 200 per mcl
WEIGHT INCREMENT      
          
Table-6
WEIGHT INCREMENT
WEIGHT (KG) MALE FEMALE
0 – 5 30 25
6 -10 11 16
11-15 5 1
≥ 16 1 2
≤ 0 5 4
TOTAL 52 48
Table – 7                
PAIRED  "T" TEST:
Pair
Paired Differences
Mean S.D S.E. of mean
99% confidence interval 
of the difference
Lower Upper
Significance 
(2 tailed) p 
value
PRE ART 
WEIGHT 
POST ART 
WEIGHT
4.59 4.675 0.4675 3.39 5.79 < 0.001
The change in weight after treatment as calculated by paired “T” test is 
statistically significant with P value < 0.001 (99% confidence interval) 
The sex does not has any influence on the weight increment . Average 
increment of weight in this study was 5kg.
Table-8
Table - 10
PAIRED  "T" TEST:
Pair
Paired Differences
Mean S.D S.E. of mean
99% confidence interval 
of the difference
Lower Upper
Significance 
(2 tailed) p 
value
PRE ART 
CD4
POST 
ART CD4
220.7 158.45 15.85 199.9 261.5 < 0.001
The change in CD4 count after treatment as calculated by 
paired “T” test is statistically significant with P value < 0.001 (99% 
confidence interval)
Table - 11
WHO STAGE IMPROVEMENT
Table - 12
WHO STAGE IMPROVEMENT
STAGE
PRE ART (O) 
MONTH
6TH MONTH OF 
ART
12TH MOHTH OF 
ART
MALE FEMALE MALE FEMALE MALE FEMALE
I 3 7 42 45 47 47
II 2 1 3 2 2 0
III 38 31 6 1 0 0
IV 9 9 1 0 3 1
TOTAL 52 48 52 48 52 48
The WHO clinical stage improvement after treatment as evidenced by 
transition in clinical staging is statistically significant with P value < 0.001.
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FUNCTIONAL STATUS IMPROVEMENT
 Table -13
FUNCTIONAL STATUS CLASS
CLASS
PRE ART (O) 
MONTH
6TH MONTH OF 
ART
12TH MOHTH OF 
ART
MALE FEMALE MALE FEMALE MALE FEMALE
BED 12 5 0 0 1 1
RIDDEN
AMBULANT 27 26 14 7 0 1
WORKING 13 17 38 41 51 46
TOTAL 52 48 52 48 52 48
Prior to ART 30% of the patient under working category, 
after 1 year of ART 97% of patients came under working 
category. There was a significant improvement in functional 
status of the patients after starting treatment.
FUNCTIONAL STATUS IMPROVEMENT
Fig-7
ART SIDE EFFECT
Fig-8
ART SIDE EFFECT
32
68
32% of the patients experienced side effects of ART. Common 
side effect observed in this study were rash, anemia, nausea vomiting.
ANALYSIS AND DISCUSSION
1. AGE AND SEX DISTRIBUTION:
In this study, the age of the patients varies from 20 years to 75 
years. The study group comprised 52 males and 48 females. 
Majority of patients belonged to the most productive age group 
of  20-40  years  (80%)  FIG –  1.  As  per  the  census  regarding   age 
distribution of AIDS cases in India, majority of HIV infections (92%) are 
in age group of 20-50 years.  The predominance of the males over the 
females is similar to the census statistics of AIDS cases in India.
2. ENTRY POINT: (TABLE-1)
In this study, 87% patients entered via VCTC (ICTC)
3. EMPLOYMENT AND RISK OF HIV (Table-2)
In  this  study,  employed  patients  (58%)  have  acquired  the 
disease.  Migrant youth are particularly vulnerable to HIV, as they may 
face  repeated risks  of  HIV  Infections.  In  this  study population  high 
prevalence of HIV observed among drivers and constructional workers.
4. FAMILY WISE DISTRIBUTION: (Table-2, Fig-3)
In  this  study,  the majority of  patients  belonged to  married 
category (80%). The widow population contributed to 9% of cases. 
In nearly, 54 out of 80 couples both husband and wife positive. 
This gives importance of preventive measures aimed at preventing  the 
transmission between the couples through education and adoption of safe 
sexual practices. 
5. HIV AND OPPORTUNISTIC INFECTION: (Fig-3)
In this study most common opportunistic infection observed are 
oral  candidiasis,  tuberculosis  ,recurrent  bacterial  infection,  Herpes 
simplex-II.
 Opportunistic  infections  were  significantly  reduced  after  highly  active 
antiretroviral therapy. This is statistically significant with P value < 0.001.
6. WEIGHT  INCREMENT  FOLLOWING  HAART: (Table-6,7,8)
In  this  study,  the  average  pre-ART weight  is  49.94kg  which 
increased to 54.53kg after ART. So an average of 5kg increases in weight 
is seen among the study group. On analyzing statistically with paired “T” 
test,  showed  a  high  statistical  significant  with  P  value  <  0.01.  4%  of 
patients  declined  in  weight  after  ART.  However,  majority   showed  an 
increment of 4.6kg after  one year of ART. 
7. ART REGIMENS: (Fig-4)
Patients taken  regimen I  accounts for 34% and  regimen  III 
accounts for 21%. The change in regimens regimen V  accounts for 
43% 
This  is  due to  the  substitution  of  Efavirenz  for  Nevirapine  in 
cases of intolerance to the latter or if patients are receiving rifampicin 
containing anti-TB treatment.32
In  this  study  the  stavudine  based  ART  regimen  is  often 
preferred to zidovudine based ART while on  initiation because of co-
existence  of  anemia  in  many  patients  making  them  unsuitable  for 
zidovudine based regimen. Success rate in I & III regimen is same.
8. TB AND HIV COINFECTION IN RELATION TO CD4 
COUNT:
In  this  study,  pulmonary  TB  (21%  of  patients)  and  Extra 
pulmonary  TB  (11%  of  patients)  were  diagnosed.  They  were  the 
second most common opportunistic infection among HIV patients, next 
to oral candidiasis. 
These patients were initially started on ATT and ART started 
subsequently after 2 weeks to 2 months as soon as TB treatment is 
tolerated. Both pulmonary and Extra pulmonary tuberculosis frequently 
occurs  in  patients  with  CD4  count  less  than  200  cells/  mcl. 
(table-4,5,Fig-5) 
9. FUNCTIONAL  STATUS  IMPROVEMENT  FOLLOWING  HAART:
The functional status of an individual is divided into three grades 
according  to  NACO,  Ministry  of  Health  and  Family  welfare, 
Government of India.
In this study, there is an improvement in functional status level 
in response to ART as evidenced by an increase in patients belonging 
to “W” class from 30% to 79% after 6 months of treatment, 97% came 
under working category after 1 year of treatment. This change in class 
is statistically significant with “P” value < 0.01. At the end of 1 year 
97% in working status 2% bed ridden, 1% ambulant. (Table-13, Fig-7).
10. WHO CLINICAL STAGE IMPROVEMENT FOLLOWING HAART:
In this study there is marked clinical  improvement after  ART. 
This reflected by the following observations.
There is an increase in clinical stage I, from 10% to 87% and clinical 
stage II from 3% to 5%.
The clinical stage II increase is mainly due to the patients who 
had improved in the clinical status from stage III to stage II.
Most  important  observation  is  the  decrease  in  stage III  from 
69% to 7% after treatment. Decrease in stage IV from 18% to 1%. At 
the  end of  1  year  94% of  patients  in  stage I,  2% in  stage II.  The 
changes are statistically significant with P value < 0.01. (table-12,Fig-6)
11. IMMUNE  RECONSTITUTION  FOLLOWING  HAART: 
 Goals  of  highly  active  antiretroviral  therapy  are  reduction  in 
plasma  RNA  levels  and  the  immune  reconstitution  (Increasing  the 
number of CD4 count and a favourable clinical outcome) 33,37,50
In this study, the mean CD4 count has increased from baseline 
81 cells /mcl to 189 cell /mcl after 6 months of ART.
The average increase in CD4 count was 108 cells /mcl.
The  statistical  analysis  done  using  paired  “T”  test  showed  a 
statistical significant, with P value < 0.001.
7% of patients showed a decline in CD4 count after treatment.
26% showed a 200 – 299 cells /mcl increment in CD count
14% showed a 100 – 199 cells /mcl  increment  in CD count
15% showed a 300 - 399 showed a 100 – 199 cells / mcl increament in 
CD count
11% showed a >400 cells /mcl increment in CD count  (table-9,10,11)
Immunological failure according to WHO in this study was seen 
in 7% of patients.
Average  CD4  count  improvement  is   -  81  cells  /mcl  after  6 
months,
108 cells /mcl after 12 months
Study  by  Kilaru   KR el   al  (2006)  had  Immunological   success 
around    80% 29,23,26
Study by Smith CJ et al  (2004)  39,46   demonstrated a median 
CD4 increase of 114 cells / mcl and Immunological success in 84% 
patients.
Vajpayee  et  al  45 showed  an  increase  of  CD4  count  from a 
median
179 cells / mcl to 256 cells / mcl after HAART for a period of 6 months.
Institute  for  infections and tropical  diseases, clinical  centre of 
Sesbia, Belgeade, and Montenegro, study result showed rise in CD4 
count to atleast 200 cells per mcl.
LP  Jacobson,  JP  phar,  TE  yamashita  –  Department  of 
epidemiology,  Johnsphopkins  university  Bloomberg  school  of  public 
health – 2004, Multicentre AIDS cohort study which show that CD4 cell 
count, history of antiretroviral therapy, age at the time of initiation are 
independent determinants of response.54,11,43
lise  p.  jacobson,  john  p.phair  and  traci  e.  yamashita  cohort 
study showed that CD4 cell count and history of ART at the time of 
initiation are independent determinants response.55
Response to HAART 52,53,13,17
IMPACT OF HAART ON PATIENTS
As per patient’s statement:
I was afraid that I would leave my family soon because I was too 
sick. But now after being started on ART I could feel the difference 
myself. Now I feel healthier and able to go to work and earn money for 
my family and me. I am happy and confident that I can live longer and 
be with my family for at least 10-15 more years.
Before ART I was roaming about doing nothing, but now after 
ART I got back my appearance and personality as before. Now I am 
going to work in manner. I am very much confident now.
I never expected that I will live. CD4 testing was done for me 
and ART were given. If ART is not inverted, mud would have eaten my 
body.  Now I  am doing so well  with ART drugs. This is actually my 
rebirth.
Therapeutic response following highly active 
antiretroviral therapy
Conclusion:
1. Majority of HIV patients belongs to reproductive age 
group.
2. Institution of HAART was associated with weight gain 
and decrease in opportunistic infection.
3. A high rate of immunological response was observed 
following HAART.
4. The Immunological and clinical response to HAART in 
HIV  infected  Tuberculosis  patients  were  similar  to 
those of Non-Tuberculosis patients.
5. Institution of HAART was associated with functional 
status improvement and mental well being.
6. 32%of patients had HIV and Tuberculosis as a co-
infection. In which 21% having pulmonary 
Tuberculosis, 11%having extrapulmonary 
Tuberculosis.
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PROFORMA
TO STUDY THE THERAPEUTIC RESPONSE FOLLOWING   HIGHLY 
ACTIVE ANTI RETROVIRAL THERAPY-AGM HOSPITAL,            
1. Name :                                                   ART NO:
2. Age :
3. Sex : M/F
4. Address :
5. Date confirmation HIV+ test :
6. Place of HIV test:
7. Entry point    :a) VCTC b)RNTCP c) O.P/I.P d) Others
8. Occupation         :
9   .Education           :
12.complaints:
13.Clinical stage assessment: (with available investigation in our   
      hospital)    
Systemic examination:
Respiratory system  :
Cardiovascular system :
Abdomem  :
Central nervous system:
WHO clinical stage    :   
14.Antiretroviral Treatment (Summary)
Treatment started SUBSTITUTION within 1st line, SWITCH to 2nd line, STOP, 
RESTART
 STV+LMV+NVP
 STV+LMV+EFV
 ZDV+LMV+NVP
 ZDV+LMV+EFV
 Others
Date Substitution
Switch/ Stop
Reaso
n
Date 
restart
New regime
17.Patient’s follow up :
                        Patient’s follow up
18.Pre and post treatment investigation
HB : gms%
TC : cells/mm3
DC :         P          L         E
ESR : mm/hr
Platelet count : lakhs/mm3
Blood Sugar : mg/dl
Blood urea : mg/dl
Serum creatinine :  mg/dl
LFT: Sr bilirubin : mg/dl
         SGOT :  U/L
             SGPT : U/L
CxR :
Sputum for AFB :
19.Others if needed :          
20.Conclusion :

